These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28892541)

  • 1. Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.
    Cole AL; Sanoff HK; Dusetzina SB
    JAMA Intern Med; 2017 Nov; 177(11):1679-1680. PubMed ID: 28892541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole AL; Dusetzina SB
    Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
    Granlund D; Bergman MA
    J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do pharmaceuticals really cost in the long run?
    Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
    Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 11. Price survey. Generic drug market heats up.
    Hosp Mater Manage; 2001 Mar; 26(3):1, 12-3. PubMed ID: 11975141
    [No Abstract]   [Full Text] [Related]  

  • 12. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of the expiry of the patent on quality and price of medicines at hospital: Study of five anticancer drugs from 2008 to 2015 at the Assistance publique-Hôpitaux de Paris].
    Siorat V; Raybaut C; Poisson N; Paubel P
    Ann Pharm Fr; 2017 Jan; 75(1):59-66. PubMed ID: 27423185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competition authority will investigate price hikes of generic drugs.
    Hawkes N
    BMJ; 2016 Nov; 355():i5849. PubMed ID: 27802935
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 19. The king of low cost drugs.
    Kimes M
    Fortune; 2009 Aug; 160(3):88-90, 92. PubMed ID: 19711707
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.